(Report ID: 174068) Drug interactions analysis of:
Methotrexate, Vincristine, Dexamethasone, Doxorubicin Hcl, Cyclophosphamide, Elspar, CytarabineMany drug interactions and side effects can not be detected until the drugs have been used by millions of people, and for a long time. Large, long-term drug safety studies are ideal to discover these real-world drug outcomes. For the first time, eHealthMe enables health professionals and patients to conduct these studies for their drugs. Click here to check your drugs now, in a whole new way. As of Nov, 20, 2008, eHealthMe analyzes 10,180,579 drug interactions and side effects of 21,667 FDA-approved drugs from 1977 to the present. Results on Nov, 20, 2008: 19 relevant incidents
Note:
- The incidents can not include all actual occurrences
- Data of 2008 is not complete
DISCLAIMER: All adverse drug reaction material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk. Basic information:
| Report ID | Date of submission | Patient age | Patient gender |
| 174068 | Jul, 27, 2006 | 15 | Male |
List of drugs the patient takes:
| Drug |
Methotrexate |
Vincristine |
Dexamethasone |
Doxorubicin Hcl |
Cyclophosphamide |
Elspar |
Cytarabine |
| Name |
Blood Luteinising Hormone Decreased |
Epiphysiolysis |
Growth Hormone Deficiency |
Insulin-like Growth Factor Decreased |
Results from eHealthMe: 19 relevent incidents1) Comparison with the patient's adverse outcomes:
| Name | Count (% of total reports) |
Blood Luteinising Hormone Decreased | 2 (10.53%) |
Epiphysiolysis | 2 (10.53%) |
Growth Hormone Deficiency | 3 (15.79%) |
Insulin-like Growth Factor Decreased | 1 (5.26%) |
Death: 0
Cancer: 0
| Name | Count (% of total reports) |
1 | Catabolic State | 1 (33.33%) |
2 | Blood Amino Acid Level Increased | 1 (33.33%) |
3 | Vomiting | 1 (33.33%) |
4 | Adenocarcinoma | 1 (33.33%) |
5 | Mass | 1 (33.33%) |
6 | Leukaemia Recurrent | 1 (33.33%) |
7 | Anorexia | 1 (33.33%) |
8 | Urinary Tract Infection Enterococcal | 1 (33.33%) |
9 | Ascites | 1 (33.33%) |
10 | Abdominal Pain | 1 (33.33%) |
3) Top co-used drugs drugs reported for the past 12 months:
| Name | Count |
1 | Mercaptopurine | 4 |
2 | Prednisone Tab | 3 |
3 | Thioguanine | 2 |
4 | Decadron | 1 |
5 | Prednisolone | 1 |
Death: 0
Cancer: 0
| Name | Count (% of total reports) |
1 | Growth Hormone Deficiency | 3 (15.79%) |
2 | Anaphylactic Shock | 2 (10.53%) |
3 | White Blood Cell Count Decreased | 2 (10.53%) |
4 | Vomiting Nos | 2 (10.53%) |
5 | Budd Chiari Syndrome | 2 (10.53%) |
6 | Epiphysiolysis | 2 (10.53%) |
7 | Blood Luteinising Hormone Decreased | 2 (10.53%) |
8 | Rash Generalised | 1 (5.26%) |
9 | Hepatic Failure | 1 (5.26%) |
10 | Myelodysplastic Syndrome Nos | 1 (5.26%) |
| Name | Count |
1 | Prednisolone | 10 |
2 | Adriamycin Pfs | 6 |
3 | Mercaptopurine | 5 |
4 | Thioguanine | 5 |
5 | Prednisone Tab | 4 |
6 | Oncovin | 3 |
7 | Vepesid | 3 |
8 | Cytosar-u | 3 |
9 | Hydrocortisone | 3 |
10 | Novantrone | 2 |
Want to have a risk analysis report like this for your drugs? Click here. ADVERTISEMENT
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- Recent drug risk analysis reports:
|
|
|
 |
|
How to use the report?
Bring a copy of this report to a doctor's appointment to ensure drug risks are fully discussed and understood, in the process of risk and benefit assessment.
|
 |
|
ADVERTISEMENT
|
|
